| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 10.02.
| Massive boost for Sligo with 175 new jobs in Abbott | | 10 | Insideireland |
| 09.02.
| A Forward Look, the Year Ahead - Featured Research on Acorda Therapeutics Inc and Abbott Laboratories | | 26 | MarketWire |
| HONG KONG -- (Marketwire) -- 02/09/12 -- Today, www.BollingerReport.com introduced featured coverage of Acorda Therapeutics Inc (NASDAQ: ACOR) and Abbott Laboratories (NYSE: ABT). Full research reports...
Mehr lesen zu:
A Forward Look, the Year Ahead - Featured Research on Acorda Therapeutics Inc and Abbott Laboratories | |
| 08.02.
| Abbott Creates New Similac SimplySmart' Baby Bottle with Innovative Features | | 28 | PR Newswire |
| ABBOTT PARK, Ill., Feb. 8, 2012 /PRNewswire/ --Abbott (NYSE: ABT)introduces Similac SimplySmart, an innovative BPA-free baby bottle designed to improve the bottle feeding experience...
Mehr lesen zu:
Abbott Creates New Similac SimplySmart' Baby Bottle with Innovative Features | |
| 07.02.
| Next Resistance Level for Abbott Laboratories is $55.95 | | 3 | SmarTrend |
| 03.02.
| Watch for Abbott Laboratories to Potentially Pullback After Gaining 1.01% Yesterday | | 7 | SmarTrend |
| 03.02.
| Abbott Laboratories Bullish Moving Average Crossover Alert | | 5 | SmarTrend |
| 02.02.
| Abbott Laboratories Approaches New Downside Target of $53.80 | | 5 | SmarTrend |
| 01.02.
| Abbott to Present at Leerink Swann 2012 Global Healthcare Conference | | 26 | PR Newswire |
| ABBOTT PARK, Ill., Feb. 1, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the Leerink Swann 2012 Global Healthcare Conference on Wednesday, Feb. 15, 2012. Thomas C. Freyman, executive vice...
Mehr lesen zu:
Abbott to Present at Leerink Swann 2012 Global Healthcare Conference | |
| 30.01.
| Here's the Problem With Abbott Laboratories | | 35 | Motley Fool |
| 30.01.
| DNDi, Abbott sign joint research, non-exclusive licensing agreement | | 4 | Pharma Bus Review |
| 30.01.
| Abbott, DNDi Enter 4-Yr Joint Research And Non-exclusive Licensing Deal | | 109 | AFX News |
| WASHINGTON (dpa-AFX) - Abbott (ABT) and the Drugs for Neglected Diseases
initiative or DNDi reached a four-year joint research and non-exclusive
licensing agreement to undertake research...
Mehr lesen zu:
Abbott, DNDi Enter 4-Yr Joint Research And Non-exclusive Licensing Deal | |
| 30.01.
| DNDi, Abbott (ABT) Enter Tropical Disease Research Agreement | | - | StreetInsider.com |
| 30.01.
| DNDi and Abbott Expand Partnership to Boost Innovation for Neglected Tropical Diseases | | 216 | PR Newswire |
| GENEVA, January 30, 2012 /PRNewswire/ --
The Drugs for Neglected Diseases initiative (DNDi) and Abbott (NYSE: ABT) have signed a four-year joint research and non-exclusive licensing agreement to...
Mehr lesen zu:
DNDi and Abbott Expand Partnership to Boost Innovation for Neglected Tropical Diseases | |
| 26.01.
| Union wants subsidies talks with Abbott | | 8 | ABC online |
| 26.01.
| The Zacks Analyst Blog Highlights: The Boeing, Lockheed Martin, Abbott Labs, Bristol-Myers Squibb and Biogen | | 82 | PR Newswire |
| CHICAGO, Jan. 26, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and...
Mehr lesen zu:
The Zacks Analyst Blog Highlights: The Boeing, Lockheed Martin, Abbott Labs, Bristol-Myers Squibb and Biogen | |
| 26.01.
| Abbott Reports Double-Digit Ongoing Earnings-Per-Share Growth in Fourth Quarter and Full-Year 2011 | | 28 | PR Newswire |
| ABBOTT PARK, Illinois, January 25, 2012 /PRNewswire/ --
-- Fourth Quarter Ongoing EPS of $1.45, Up 11.5 Percent --
-- On Track to Separate into Two Leading Health Care Companies --
Abbott (NYSE:...
Mehr lesen zu:
Abbott Reports Double-Digit Ongoing Earnings-Per-Share Growth in Fourth Quarter and Full-Year 2011 | |
| 25.01.
| Abbott Labs cuts 700 jobs amid drop in heart stent orders, posts higher 4Q profit | | 24 | Yahoo-CAN |
| 25.01.
| Abbott Laboratories Beats Estimates Yet Again | | 5 | Motley Fool |
| 25.01.
| Significantly Favorable Risk/Reward For Abbott, Merck | | 4 | Seeking Alpha |
| 25.01.
| Abbott Beats on EPS, Guides In-Line | | - | Zacks |
